{
  "id": 9147074,
  "title": "Natera Inc stock reaches all-time high at 373.58 USD",
  "url": "https://urgent.news/2026/09/22/natera-inc-stock-reaches-all-time-high-at-373-58-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T13:43:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/natera-inc-stock-reaches-alltime-high-at-37358-usd-93CH-4911061"
  },
  "original_language": "en",
  "account": "On an impressive day for Natera Inc, the company's stock hit an all-time high, trading at $373.58, just $0.13 above its 52-week peak of $373.07. The stock showed robust growth, rising by 5.7% in a single week and an outstanding 89.8% increase over the past six months. In the yearly timeframe, the stock surged by a notable 112.67%. This surge illustrates the company's solid performance and investor confidence, bolstered by a revenue growth of 37.8% over the last year. The achievement underscores Natera Inc's upward trajectory in the stock market. Despite being deemed overvalued by InvestingPro analysis, the stock remains a compelling investment option. For a deeper understanding of Natera's valuation and growth prospects, investors can explore 16 additional InvestingPro Tips and a detailed Pro Research Report. Recently, Natera reported solid second-quarter earnings, with revenue reaching about $753 million, exceeding Wall Street's expectation of $661.26 million. This growth is attributed to accelerated expansion across core businesses, notably driven by record test volumes, improved margins, and regulatory successes. Management has also elevated its full-year revenue outlook, citing robust test volumes, enhanced margins, and significant regulatory victories. Moreover, Rothschild Redburn has taken a bullish stance on Natera, assigning it a Buy rating with a price target of $385. The recommendation highlights Natera's pioneering role in minimal residual disease testing with the Signatera test and the development of a multi-cancer early detection screening test, further solidifying the company's industry leadership. This report was co-produced through the assistance of AI and editorial review, ensuring accuracy and reliability.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}